Add BrightSurf on Google Email

New study unveils the human and scientific dimensions of IPCC sea level rise projections

Researchers from Indiana University and Princeton University provide an unprecedented look at the collaborative process that determines IPCC's sea level rise projections. The study highlights challenges in reconciling conflicting methodologies while maintaining scientific integrity.

SourcePrinceton School of Public and International Affairs·JournalGlobal Environmental Change·TypeObservational study·DateDec 2, 2024

When club teammates become World Cup rivals

A new study examines the hidden tension when coworkers compete on behalf of rival organizations, using soccer players as a case study. The researchers found that teammates who competed against each other on opposing national teams reduced collaboration within their shared clubs, passing the ball to each other around 11% less often in t...

SourceBocconi University·JournalStrategic Management Journal·DateNov 26, 2024

Team unlocks new insights on pulsar signals

A study published in The Astrophysical Journal reveals that pulsar signals change as they move through the interstellar medium, highlighting a need for updates to current ISM density models. The research found that models incorporating galactic structures tend to better fit the data, but predictions of newly discovered pulsars were worse.

SourceSETI Institute·JournalThe Astrophysical Journal·DateNov 26, 2024

Unmasking the voices of experience in healthcare studies

Researchers at Flinders University advocate for a formal process to acknowledge the valuable contributions of those with lived experience in healthcare research. The study highlights the importance of recognizing their value and increasing visibility, with over 70% of contributors wanting public recognition.

SourceFlinders University·JournalPatient Education and Counseling·TypeSurvey·DateNov 25, 2024

Stand Up to Cancer collaborates with Johnson & Johnson to explore targeted therapies for rare disease linked to blood cancers

A new research project will test a combination of two targeted therapies, teclistamab and daratumumab, to treat AL amyloidosis, a rare disease affecting approximately 4,500 people annually in the U.S. The study aims to leverage previous findings from multiple myeloma to expand understanding of this treatment option.

SourceStand Up To Cancer·TypeNews article·DateNov 11, 2024